 Home > Active Ingredient News >

Antitumor Therapy

Blood: MiR-146a deficiency links IL6/TNFD induced inflammation to myelin malignancies

 Time of Update: 2020-06-16

bone cell function omega 6 inflammation aml cells inflammatory cells meds inflammation

Aging is associated with significant changes in the hematopoietic system, including increased inflammation, impaired function of hematopoietic stem cells (HSC) and increased incidence of myelin malig
Lancet: Atezolizumab-Vemurafenib-Cobimetinib first-line treatment for advanced BRAF V600 mutant positive melanoma

 Time of Update: 2020-06-16

3 4 water plastics 1 7 10 8 performance 1 3 diaminopropane advanced wastewater treatment

The IMspire150 study, which aims to evaluate the treatment of BRAF, MEK inhibitors and combined immunocheckpoint inhibitors for braF V600 mutant-positive late-stage or metastatic melanoma, was recent
Lancet oncol: Phase III Trial: The Efficacy and Safety of Ripretinib Single Drug for the Treatment of Late Gastroenteric Tumors

 Time of Update: 2020-06-16

2 4 dibromophenol 1 5 dilution 1 3 dilution 3 4 7 8 pilocarpine 5 mg

Resistance to approved KIT primary cancer genes, receptor tyrosine kinase (KIT) and platelet-source growth factor receptor (PDGFRA) inhibitors is a clinical challenge for patients with advanced gastr
Blood: Effect of human-derived Fc receptor non-binding anti-CD3 monoclonal antibodies in T-ALL

 Time of Update: 2020-06-16

faslodex side effects lupus side effects cystex side effects arformoterol side effects abacavir side effects

T-cell acute lymphoblastic leukemia (T-ALL) is an invasive malignant tumor that accounts for about 20% of ALL cases Intensive chemotherapy regimens have a cure rate of more than 85%, but less than 50
Blood: HLA-B pilot genotype predicts hlA mismatch with prognosis of bloodless donor HCT

 Time of Update: 2020-06-16

11 64 mm blood cell size rare blood disease site factors 1 strategy

Hematopoietic cell transplantation (HCT) from hlA mismatched non-blood-related donors can cure life-threatening blood diseases, but its success rate is limited by graft-resistant host disease (GVHD)
EHA 2020: Latest advances in Roche's CD20xCD3 dual-specific antibody glofitamab treatment for lymphoma

 Time of Update: 2020-06-16

gold number 1 abc 1 2 ocean surface area new treatment tourette's c4 2 form

At the 25th annual meeting of the European Society of Hematology, Roche announced the latest data on its CD20xCD3 T-cell bispecific antibody glofitamab (formerly known as CD20-TCB) for patients with
Lancet oncol: Clinical characteristics and risk factors for cancer patients infected with the new coronavirus in Wuhan

 Time of Update: 2020-06-16

risk free 1 2 propanediol 1 6 diaminohexane pancreatic cancer association 1 3 cyclohexanedione

COVID-19 has spread around the world Cancer patients are reported to be epidemiologically sensitive to the new coronavirus The purpose of this study is to systematically describe the clinical charact
CD20xCD3 bispecific antibodies! Roche glofitamab treatment for recurrent/refractive non-Hodgkin's lymphoma (NHL) shows strong results!

 Time of Update: 2020-06-16

cancer patient non processed foods non metastatic 1 4 dichlorobutane group 10

JUNE 14, 2020 /PRNewswire/ -- Roche recently released the latest data on CD20xCD3 T cells binding bispecific antibody glofitamab (formerly known as CD20-TCB) for recurrent or refractive (R)non-Hodgkin
Example: Analysis of expression differences between cancer and cancer-side tissue using TCGA database

 Time of Update: 2020-06-16

bulk coconut water bulk mct oil bulk beeswax pellets bulk organic spices expert analysis

Example: How to analyze the expression difference between LINC00152 in ovarian cancer and normal tissue using the TCGA database? So with this topic as a record analysis process as follows: First, dow
First-line immunotherapy for bladder cancer! Merck/Pfizer Bavencio Maintenance Therapy Phase III clinically significantly superior to standard care, extending patient survival!

 Time of Update: 2020-06-16

scopolamine drug rbc 3 10 deodorant cause cancer skin body care products loc care

JUNE 11, 2020 /PRNewswire/ -- Pfizer and partner Merck KGaA have announced the total survival results of the phase-by-phase analysis of the anti-PD-L1 therapy Bavencio (avelumab) first-line maintenanc
Blood: New demethylation drug OR-2100 targets treatment of DNA abnormal supermethylation-driven ATL leukemia

 Time of Update: 2020-06-16

anti ds dna test 1 cell phone patient derived xenograft line huntsville al 1 3 dibromopropane

Adult T-cell leukemia - lymphoma (ATL) is an invasive CD4-T cell blood tumor transformed by human T-cell lymphatic virus-1 (HTLV-1) Most individuals infected with HTLV-1 are asymptomatic, and only 3-
FDA: Approves second-line treatment of navulyo monoantine approved esophageal squamous cancer

 Time of Update: 2020-06-16

keratin conditioning treatment wolf cell sorter car cell treatment food safety quiz bond analysis

Esophageal cancer is a common digestive tumor, compared with Europe and the United States, the incidence of esophageal cancer in China is higher, and has a certain degree of regional differences Euro
First sound pharmaceutical industry to Hong Kong stock exchange listing, 3 key products are expected to be listed in the next two years!

 Time of Update: 2020-06-16

ritalin drug cancer drug names used 10 22 lama drug rubbing alcohol target

The latest announcement of the Hong Kong Stock Exchange indicates that First Sound Pharmaceuticals has submitted an application for listing in accordance with Section 8.12 of the Listing Rules Accord
Nature: Tumor metabolites disrupt chromatin signals and inhibit DNA repair

 Time of Update: 2020-06-16

dna polymerase 3 2 3 dimethylheptane breast cancer cells 2 ethylhexanoic acid 2 propenoic acid

Metabolic disorders and the destruction of genomic integrity are the main markers of cancer Increased levels of metabolites 2-hydroxypronoric acid, semacid and fumatate are found in human malignancie
Br J Cancer: SLFN5 regulates epithelial interstitial transformation process affects breast cancer metastasis

 Time of Update: 2020-06-16

low ferritin treatment cancer smell merck cancer drug breast cancer receptors region

Previous studies have found that the Slfn family of mice is involved in a variety of physiological or pathological processes, including T-cell activation, thymus cell maturation, fibroblast splinter
Blood: A small number of T-cells that identify tumor-related antigens stimulate antitumor response

 Time of Update: 2020-06-16

hla antigen block number 3 plasma cells blood 1 inch 16 ny eso 1

Tumor-related antigen (TAA) is a monomorphic self-antigen that is considered an immunotherapy target for malignant tumors Is it possible to find T-cells with sufficient affinity in the T-cell pool of
Breast Cancer Treat: Palbociclib Calais as estrogen receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer treatment effects

 Time of Update: 2020-06-16

lung cancer biomarkers super 4 line group 4 1 2 4 trichlorobenzene protein cancer

In the initial PALOMA-2 (NCT01740427) analysis, the median follow-up was 23 months, and palbociclib calais can significantly prolong estrogen receptor-positive (ER-plus)/human epidermal growth factor
NICE UK approves Roche's PD-L1 single anti-Tecentriq treatment for triple-negative breast cancer after offering big discount

 Time of Update: 2020-06-16

2 3 butanediol pd l1 antibody gamma 1 3 1 2 addition silicone 1 2

The National Institute of Health and Clinical Excellence (NICE) has approved its immunotherapy PD-L1 monoantiticriq (atezolizumab) for the treatment of triple-negative breast cancer (TNBC) patients a
1 case of imaging performance of adrenal melanoma

 Time of Update: 2020-06-16

scan blood clots coffee blood thinner blood worms teeth 1 1 figure calculate cell density

The case of the male, 49 years old, a medical examination found that the right adrenal area of the swelling, had a history of fainting Deny the history of chronic diseases such as "hypertension, coro
Light chain (AL) amyloid degeneration first therapy! Johnson and Johnson subcutaneous Darzalex combination first-line therapy Phase III Clinical: Hematology remission rate as high as 92%

 Time of Update: 2020-06-16

noonan syndrome treatment light soda proteins function 25 kidney function bacitracin generic name

June 14, 2020 /PRNewswire/ -- Janssen Pharmaceuticals, owned by Johnson and Johnson (JNJ), recently announced the positive results of the Phase III ANDROMEDA study at the 25th annual meeting of the Eu

Go to Page

Antitumor Therapy

Blood: MiR-146a deficiency links IL6/TNFD induced inflammation to myelin malignancies

Lancet: Atezolizumab-Vemurafenib-Cobimetinib first-line treatment for advanced BRAF V600 mutant positive melanoma

Lancet oncol: Phase III Trial: The Efficacy and Safety of Ripretinib Single Drug for the Treatment of Late Gastroenteric Tumors

Blood: Effect of human-derived Fc receptor non-binding anti-CD3 monoclonal antibodies in T-ALL

Blood: HLA-B pilot genotype predicts hlA mismatch with prognosis of bloodless donor HCT

EHA 2020: Latest advances in Roche's CD20xCD3 dual-specific antibody glofitamab treatment for lymphoma

Lancet oncol: Clinical characteristics and risk factors for cancer patients infected with the new coronavirus in Wuhan

CD20xCD3 bispecific antibodies! Roche glofitamab treatment for recurrent/refractive non-Hodgkin's lymphoma (NHL) shows strong results!

Example: Analysis of expression differences between cancer and cancer-side tissue using TCGA database

First-line immunotherapy for bladder cancer! Merck/Pfizer Bavencio Maintenance Therapy Phase III clinically significantly superior to standard care, extending patient survival!

Blood: New demethylation drug OR-2100 targets treatment of DNA abnormal supermethylation-driven ATL leukemia

FDA: Approves second-line treatment of navulyo monoantine approved esophageal squamous cancer

First sound pharmaceutical industry to Hong Kong stock exchange listing, 3 key products are expected to be listed in the next two years!

Nature: Tumor metabolites disrupt chromatin signals and inhibit DNA repair

Br J Cancer: SLFN5 regulates epithelial interstitial transformation process affects breast cancer metastasis

Blood: A small number of T-cells that identify tumor-related antigens stimulate antitumor response

Breast Cancer Treat: Palbociclib Calais as estrogen receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer treatment effects

NICE UK approves Roche's PD-L1 single anti-Tecentriq treatment for triple-negative breast cancer after offering big discount

1 case of imaging performance of adrenal melanoma

Light chain (AL) amyloid degeneration first therapy! Johnson and Johnson subcutaneous Darzalex combination first-line therapy Phase III Clinical: Hematology remission rate as high as 92%